KORU Medical Systems, Inc. (NASDAQ:KRMD) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Louisa Smith - Investor Relations Linda Tharby - President & Chief Executive Officer Tom Adams - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Anderson Shack - B. Riley Securities Caitlin Croning - Canaccord Genuity Operator Ladies and gentlemen, greetings, and welcome to the KORU Medic ...

KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.02, delivering a surprise of 50%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. KORU Medical Systems Inc., whic ...

KORU Medical Systems Q3 2024 Earnings Call November 13, 2024 1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 regarding our expectations for future performance, including but not limited to the existence and timing of potential drug launches, the success and timing of our novel therapies collaborations, our future financial performance (including but not limited t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-30 ...

EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q3 FINANCIAL RESULTS, THIRD CONSECUTIVE QUARTER OF DOUBLE-DIGIT GROWTH; RAISES FULL YEAR 2024 GUIDANCE MAHWAH, NJ – November 13, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended Septe ...

KORU Medical Systems, Inc (NASDAQ:KRMD) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Louisa Smith - Investor Relations Linda Tharby - President and CEO Tom Adams - Chief Financial Officer Conference Call Participants Caitlin Croning - Canaccord Genuity Nelson Cox - Lake Street Capital Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the KORU Medical Systems Second Quarter 2024 Earnings Call. At this time, all participants are in a listen- ...

KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.02, delivering a surprise of 50%. Over the last four quarters, the company has su ...

EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q2 FINANCIAL RESULTS, A RECORD QUARTER WITH 22% REVENUE GROWTH; RAISES FULL YEAR 2024 GUIDANCE MAHWAH, NJ – August 7, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2024 a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3044880 ...

Tom Adams Our first quarter gross margin improved to 62.3%, a 620 basis point increase compared to the prior year. As indicated on the bar graph on the right side. The strong improvement was largely due to the consolidation of our U.S. manufacturing sites. This marks the third consecutive quarter that we have achieved margins greater than 60%, and we continue to work diligently to realize manufacturing improvements and efficiencies across our operations. Additionally, we have improved gross margins realized ...